Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Hatem Ali, MBBS, Baharani Jyoti, MBBS, FRCP, Shankaranarayana Paneesha, MD, Richard Lovell, Alex George Kanellopoulos, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Lorna Cain, Maria Kaparou, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath

Blood (2016) 128 (22): 5822.

https://doi.org/10.1182/blood.V128.22.5822.5822

Published: 2016

Journal Articles

Single Centre Experience of Managing Patients with Double Hit Lymphoma

Shankaranarayana Paneesha, MD FRCP, FRCPath, Iman Qureshi, MBBS, MRCP, Malahat Saeed, MBBS MRCP, Richard Lovell, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath, Kathy Holder, Maria Kaparou

Blood (2016) 128 (22): 5868.

https://doi.org/10.1182/blood.V128.22.5868.5868

Published: 2016

Journal Articles

12-Month Full Donor Chimerism Is Associated with Low-Grade Acute Graft Versus Host Disease (aGVHD) and Predicts Superior Outcomes in Reduced Intensity (RIC) Alemtuzumab-Based Transplants for MDS and AML

Alex George Kanellopoulos, MD, Shankaranarayana Paneesha, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Dewi Tomos Eden, MRCP,MB,FRCPath, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Lorna Cain, Carolina Arbuthnot, Richard Lovell, Anton Borg, MDFRCP,FRCPath, Katie Randall, MB, FRCPath, Kathy Holder, Julie Suhr, Lynda Baker, Lynn Ryan, Maria Kaparou, Bhuvan Kishore, MBBS, MRCP, FRCPath, Emmanouil Nikolousis, PhD MBBS, FRCPath, MBA

Blood (2016) 128 (22): 5764.

https://doi.org/10.1182/blood.V128.22.5764.5764

Published: 2016

Journal Articles

A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma

Richard S Whitmill, MBCHB FRCPath, David J Lewis, David John Sutton, MBBChir, MRCP, BSc, Jahanzeb Khawaja, MB CHB MRCP, Georgina Mayer, MB CHB MRCP, Shankaranarayana Paneesha, MD, Emmanouil Nikolousis, PhD, Bhuvan Kishore, MBBS, FRCPATH, MRCP

Blood (2015) 126 (23): 1898.

https://doi.org/10.1182/blood.V126.23.1898.1898

Published: 2015

Journal Articles

Colony Stimulating Factors (Pegfilgrastim or Lenograstim) Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay with No Impact on Progression Free Survival (PFS) or Overall Survival (OS)

Georgina Mayer, Bhuvan Kishore, MBBS, FRCPATH, MRCP, Richard Lovell, Emmanouil Nikolousis, PhD, Shankaranarayana Paneesha, MD FRCP, FRCPath

Blood (2015) 126 (23): 5450.

https://doi.org/10.1182/blood.V126.23.5450.5450

Published: 2015

Journal Articles

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Andrew McMillan, FRCP, FRCPath, PhD, Kirit M Ardeshna, FRCPath, Jo Gambell, Andrew Jack, PhD, Amy Kirkwood, Anthony Laurie, Silvia Montoto, MD, Shankaranarayana Paneesha, MD, Simon Rule, MD, Russell Patmore, MD, Ruth Pettengell, Humra Shah, Paul Smith, David Linch, FMedSci

Blood (2013) 122 (21): 4348.

https://doi.org/10.1182/blood.V122.21.4348.4348

Published: 2013

Journal Articles

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Emmanouil Nikolousis, Charles F. Craddock, BM, MRCP, MRCPath, Shankaranarayana Paneesha, MD, Sudhir Tauro, Prem Mahendra, II, Mark Cook, Fiona Clark, Richard Lovell, Sridhar Chaganti, Donald Milligan, MD, MBChB, Dominique Mcmullan, Mike Griffiths, Stephen P Robinson, MD

Blood (2008) 112 (11): 4409.

https://doi.org/10.1182/blood.V112.11.4409.4409

Published: 2008

Journal Articles

Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study

Shankaranarayana Paneesha, MD, Aidan McManus, PhD, Roopen Arya, MBBS, PhD, Nicholas Scriven, MB, Tim Nokes, MD, Timothy Farren, BSc, Sue Bacon, SRN, Anthea Nieland, SRN, Denise O’Shaughnessy, MD, PhD, Peter Rose, MD

Blood (2008) 112 (11): 3826.

https://doi.org/10.1182/blood.V112.11.3826.3826

Published: 2008

Journal Articles

Transplant Outcome Is Not Affected by Body Mass Index (BMI) in Patients with Haematological Malignancies.

Emmanouil Nikolousis, Shankaranarayana Paneesha, MD MRCP MRCPath, Kathy Holder, Lynn Bratby, Srinivas Pillai, Richard Lovell, Don Milligan, MD FRCP FRCPath

Blood (2007) 110 (11): 1991.

https://doi.org/10.1182/blood.V110.11.1991.1991

Published: 2007

Journal Articles

Derivation and Validation of a Prediction Tool for Venous Thromboembolism: A VERITY Registry Study.

Roopen Arya, MB, PhD, Shankaranarayana Paneesha, MD, Aidan McManus, PhD, Nick Parsons, PhD, Nicholas Scriven, MBBS, Tim Farren, BSc, Tim Nokes, MD, Denise O’Shaughnessy, MD, PhD, Peter Rose, MD

Blood (2007) 110 (11): 697.

https://doi.org/10.1182/blood.V110.11.697.697

Published: 2007

Journal Articles

Bone Marrow Fibrosis Is a Negative Predictor for Osteolytic Lesions in Patients with Myeloma.

Shankaranarayana Paneesha, MD, MRCP, MRCPath, Raj Pol, N. Chachlani, Guy Pratt, Peter Rose, Anton Borg

Blood (2006) 108 (11): 5059.

https://doi.org/10.1182/blood.V108.11.5059.5059

Published: 2006

Journal Articles

BAX UTR G (-248) A Polymorphism Has No Impact on Survival in Patients with Multiple Myeloma.

Shankaranarayana Paneesha, MD, MRCP, MRCPath, K. Hawkins, F. Davies, L. Hooper, J. Starczynski, C. Pepper, Gareth Morgan, C. Fegan, Guy Pratt

Blood (2006) 108 (11): 5022.

https://doi.org/10.1182/blood.V108.11.5022.5022

Published: 2006

Journal Articles

Upregulation of MMP-2 & 9 by Co-Culture of Human Myeloma Cell Lines and Endothelial Cells May Be Responsible for Protection Against Cytotoxic Drugs.

Shankaranarayana Paneesha, MD, MRCP, MRCPath, Raghu Adya, Hemali Khanji, Ed Leung, C. Vijayasekar, Guy Pratt, Anton Borg, Peter Rose, Alan Morris

Blood (2006) 108 (11): 5080.

https://doi.org/10.1182/blood.V108.11.5080.5080

Published: 2006

Journal Articles

A Predictive Model To Identify Patients with Venous Thromboembolism (VTE) at Minimal Risk of Malignancy.

Shankaranarayana Paneesha, MD, MRCP, MRCPath, W. Zhang, N. Parsons, K. French, E. Cheyne, S. Bacchu, Anton Borg, P. Rose

Blood (2006) 108 (11): 1500.

https://doi.org/10.1182/blood.V108.11.1500.1500

Published: 2006

NARROW

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Single Centre Experience of Managing Patients with Double Hit Lymphoma

12-Month Full Donor Chimerism Is Associated with Low-Grade Acute Graft Versus Host Disease (aGVHD) and Predicts Superior Outcomes in Reduced Intensity (RIC) Alemtuzumab-Based Transplants for MDS and AML

A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Pretransplant Characteristics Could Predict Full Donor Chimerism on Day +90 and Day +180 and Outcomes in Reduced Intensity Alemtuzumab Conditioning Allogeneic Transplantation Can Be Influenced by Chimeric Status

Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study

Transplant Outcome Is Not Affected by Body Mass Index (BMI) in Patients with Haematological Malignancies.

Derivation and Validation of a Prediction Tool for Venous Thromboembolism: A VERITY Registry Study.

Bone Marrow Fibrosis Is a Negative Predictor for Osteolytic Lesions in Patients with Myeloma.

BAX UTR G (-248) A Polymorphism Has No Impact on Survival in Patients with Multiple Myeloma.

Upregulation of MMP-2 & 9 by Co-Culture of Human Myeloma Cell Lines and Endothelial Cells May Be Responsible for Protection Against Cytotoxic Drugs.

A Predictive Model To Identify Patients with Venous Thromboembolism (VTE) at Minimal Risk of Malignancy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only